CliffBio
biologic

Loqtorzi

toripalimab-tpzi

Loss of exclusivityOctober 2035projected — 12-year biologic exclusivity estimate
CompanyCoherus BioSciences →See this company's full patent-cliff portfolio

Drug detail

Brand nameLoqtorzi
Active ingredienttoripalimab-tpzi
Strength240MG/6ML (40MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalOctober 2023
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.